Outset Medical, Inc. (OM)
NASDAQ: OM · Real-Time Price · USD
3.490
-0.150 (-4.12%)
At close: Feb 27, 2026, 4:00 PM EST
3.640
+0.150 (4.30%)
After-hours: Feb 27, 2026, 7:00 PM EST

Company Description

Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States.

The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.

It also offers Tablo Data Ecosystem, including TabloHub, a consumer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform.

The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015.

Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

Outset Medical, Inc.
Outset Medical logo
CountryUnited States
Founded2003
IPO DateSep 15, 2020
IndustryMedical Devices
SectorHealthcare
Employees310
CEOLeslie Trigg

Contact Details

Address:
3052 Orchard Drive
San Jose, California 95134
United States
Phone669 231 8200
Websiteoutsetmedical.com

Stock Details

Ticker SymbolOM
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$27.00
CIK Code1484612
CUSIP Number690145206
ISIN NumberUS6901452069
Employer ID20-0514392
SIC Code3845

Key Executives

NamePosition
Leslie L. TriggPresident, Chief Executive Officer and Chairman
Renee M. GaetaChief Financial Officer, Principal Financial Officer and Principal Accounting Officer
James S. MazzolaVice President of Corporate Communications and Investor Relations
Amelia MerrillVice President of People Operations and Culture
Dr. Michael Aragon M.D.Chief Medical Officer
Dinamarie StefaniSenior Vice President of Regulatory Affairs and Quality Assurance
Brittni McGillChief Nursing Officer
Brett FoggSenior Vice President of Research & Development and Operations
John GeraciVice President and Controller

Latest SEC Filings

DateTypeTitle
Feb 17, 2026144Filing
Feb 17, 2026144Filing
Feb 17, 2026SCHEDULE 13G/AFiling
Feb 17, 2026SCHEDULE 13G/AFiling
Feb 13, 2026SCHEDULE 13G/AFiling
Feb 13, 2026S-8Securities to be offered to employees in employee benefit plans
Feb 13, 202610-KAnnual Report
Feb 11, 20268-KCurrent Report
Feb 11, 2026SCHEDULE 13GFiling
Jan 27, 20268-KCurrent Report